NACLC 2022 | Mechanisms of resistance to KRAS G12C inhibitors

Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, describes resistance mechanisms to sotorasib and adagrasib, two KRAS G12C inhibitors indicated for non-small cell lung cancer (NSCLC). Resistance can either be primary resistance or acquired resistance, with common off target mechanisms being via the MAP or mTOR pathways. Tumor profiling will additionally play a key role in identifying patients who have progressed on existing inhibitors. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.